Pharmaceutical formulations of ecteinascidin compounds
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/50
A61K-031/495
A61K-031/715
A61K-047/26
A61K-047/18
A61K-047/32
A61K-047/02
A61K-009/19
A61K-031/498
A61K-031/4995
A61K-009/00
출원번호
US-0261876
(2005-10-28)
등록번호
US-8895557
(2014-11-25)
발명자
/ 주소
Beijnen, Jacob Hendrik
Nuijen, Bastiaan
Salve, Pilar Calvo
Barreira, Maria Tobio
출원인 / 주소
Pharma Mar, S.A., Sociedad Unipersonal
대리인 / 주소
Sonnenfeld, Kenneth H.
인용정보
피인용 횟수 :
0인용 특허 :
20
초록
Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
대표청구항▼
1. A lyophilised anti-tumor composition comprising a single active anti-tumor compound and a disaccharide selected from sucrose, lactose and a combination thereof, wherein the anti-tumor compound is ET-743 and wherein the disaccharide is present in a sufficient amount to inhibit conversion of the ET
1. A lyophilised anti-tumor composition comprising a single active anti-tumor compound and a disaccharide selected from sucrose, lactose and a combination thereof, wherein the anti-tumor compound is ET-743 and wherein the disaccharide is present in a sufficient amount to inhibit conversion of the ET-743 into ET-701, such that the ET-743 composition comprises less than 2% ET-701 after storage of the ET-743 composition at 5° C. for 3 months. 2. The lyophilised anti-tumor composition according to claim 1, wherein said disaccharide is lactose. 3. The lyophilised anti-tumor composition according to claim 1, wherein said disaccharide is sucrose. 4. The lyophilised anti-tumor composition according to claim 1, wherein the ratio (w/w) of ET-743 to disaccharide is from about 1:100 to about 1:1500. 5. The lyophilised anti-tumor composition according to claim 4, wherein the ratio (w/w) of ET-743 to disaccharide is from about 1:250 to about 1:600. 6. The lyophilised anti-tumor composition according to claim 5, wherein the ratio (w/w) of ET-743 to disaccharide is about 1:400. 7. The lyophilised anti-tumor composition according to claim 1, which further comprises a buffering agent. 8. The lyophilised anti-tumor composition according to claim 7, wherein said buffering agent is selected from phosphate buffer, citrate buffer, glycine/hydrochloric acid buffer, and mixtures thereof. 9. The lyophilised anti-tumor composition according to claim 1, which further comprises a surface-active agent. 10. The lyophilised anti-tumor composition according to claim 9, wherein the surface-active agent is selected from polyoxyethylene 20 sorbitan monooleate, polyoxyl 40 stearate, and mixtures thereof. 11. The lyophilised anti-tumor composition according to claim 1, wherein the lyophilised formulation is in a vial. 12. The lyophilised anti-tumor composition according to claim 11, wherein ET-743 is present in an amount of about 250 micrograms. 13. The lyophilised anti-tumor composition according to claim 12, wherein said vial contains a composition comprising: about 0.25 mg ET-743, about 100 mg sucrose, and about 6.8 mg potassium dihydrogen phosphate. 14. The lyophilised anti-tumor composition according to claim 11, wherein ET-743 is present in an amount of about 1 mg. 15. The lyophilised anti-tumor composition according to claim 14, wherein said vial contains a formulation comprising: about 1.0 mg ET-743, about 400 mg sucrose, and about 27.2 mg potassium dihydrogen phosphate. 16. A method of making a lyophilised composition of ET-743 according to claim 1, comprising freeze-drying a bulk solution that comprises ET-743 and a disaccharide wherein said disaccharide is selected from sucrose, lactose and a combination thereof. 17. A method of reducing the formation of ET-701 in a composition of ET-743, comprising freeze-drying a bulk solution that comprises ET-743 and a disaccharide to yield a composition according to claim 1 wherein said disaccharide is selected from sucrose, lactose and a combination thereof. 18. A method of preparing a bulk solution for lyophilising to yield a composition according to claim 1, comprising dissolving ET-743 in an acidic medium, mixing the pre-dissolved ET-743 with other components of the bulk solution and, optionally, adjusting the pH of the final solution. 19. A method of preparing a solution for intravenous infusion, comprising: providing a vial that comprises a lyophilised ET-743 composition according to claim 1, adding water to form a reconstituted solution, and diluting said reconstituted solution with an aqueous system. 20. The lyophilised anti-tumor composition according to claim 3, further comprising a buffering agent. 21. The lyophilised anti-tumor composition according to claim 20, further comprising a surface-active agent. 22. A lyophilized anti-tumor composition comprising a single active anti-tumor compound and a disaccharide selected from sucrose, lactose and a combination thereof, wherein the anti-tumor compound is ET-743 and wherein the disaccharide is present in a sufficient amount to inhibit conversion of the ET-743 into ET-701, such that the ET-743 composition comprises less than 2% ET-701 after storage of the ET-743 composition at 25° C. for 3 months. 23. The lyophilised anti-tumor composition according claim 22, wherein the lyophilised composition is in a vial. 24. The lyophilised anti-tumor composition according to claim 22, wherein the disaccharide is sucrose. 25. The lyophilised anti-tumor composition according to claim 22, wherein the disaccharide is lactose. 26. The lyophilised anti-tumor composition according to claim 22, further comprising a buffer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (20)
Brana Miguel F. (Avenida de Burgos No. 20 ; 10M. ES-28036 ; Madrid ESX) Castellano Berlanga JoseM. (Avenida de Burgos No. 20 ; 10M. ES-28036 ; Madrid ESX) Moran Moset Marina (50, 5-nitrobenzo[de]isoquinoline-1,3-diones their preparation and their use.
Rinehart Kenneth (Urbana IL) Ryuichi Sakai (Urbana IL) Holt Tom G. (Westfield NJ), Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith.
Cuevas,Carmen; Perez,Marta; Francesch,Andres; Fernandez,Carolina; Chicharro,Jose Luis; Gallego,Pilar; Zarzuelo,Maria; de la Calle,Fernando; Manzanares,Ignacio, Hemisynthetic method and new compounds.
Martin Francis J. (San Francisco CA) Woodle Martin C. (Menlo Park CA) Redemann Carl (Walnut Creek CA) Yau-Young Annie (Palo Alto CA), Solid tumor treatment method and composition.
Francesch,Andr��s; Fern��ndez,Carolina; Chicharro,Jos�� Luis; Gallego,Pilar; Zarzuelo,Maria; Manzanares,Ignacio; Perez,Marta; Cuevas,Carmen; Martin,Mar��a Jes{dot over (u)}s; Munt,Simon, Synthetic process for the manufacture of an ecteinaschidin compound.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.